Background There is no clear consensus on whether aspirin offers better outcomes in terms
of secondary cardiovascular disease prevention compared with clopidogrel. Objective The …

Background The benefits and risks of aspirin verse clopidogrel monotherapy in patients with
coronary artery disease (CAD) remain controversial. This meta-analysis evaluated the …

Objectives To quantify the impact of clopidogrel plus aspirin on the individual outcomes of
death, myocardial infarction, or stroke in patients with established cardiovascular disease, or …

Background Aspirin and clopidogrel monotherapies are effective treatments for preventing
vascular disease. However, new evidence has emerged regarding the use of combined …

Antiplatelet agents are central to the treatment and prevention of cardiovascular disease.
Although aspirin is the most widely used agent, randomized trials have assessed whether …

Background Aspirin is the prophylactic antiplatelet drug of choice for people with
cardiovascular disease. However, protection with antiplatelet therapy in people with a high …

Background Aspirin is the prophylactic antiplatelet drug of choice for people with
cardiovascular disease. Adding a second antiplatelet drug to aspirin may produce additional …

Background and Purpose—In the Secondary Prevention of Small Subcortical Strokes
(SPS3) trial, addition of clopidogrel to aspirin was associated with an unexpected increase …

BACKGROUND: Many clinical trials have evaluated the benefit of long-term use of
antiplatelet drugs in reducing the risk of clinical thrombotic events. Aspirin and ticlopidine …

Dual antiplatelet therapy with acetylsalicylic acid (aspirin) and clopidogrel is a guideline-
recommended standard of care for patients with acute coronary syndromes (ACS) and those …